CoChat

A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer

Open access
Moore, Kathleen N., Gunderson, Camille C., Sabbatini, Paul, McMeekin, D. Scott, Mantia-Smaldone, Gina, Burger, Robert A., Morgan, Mark A., Kapoun, Ann M., Brachmann, Rainer Karl, Stagg, Robert, Farooki, Azeez, O'Cearbhaill, Roisin E. · 2019 · Gynecologic Oncology
Cited by 104

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Objectives: The WNT pathway is an important oncologic driver of epithelial ovarian cancer (EOC). The first-in-class recombinant fusion protein ipafricept (IPA) blocks Wnt signaling through binding of Wnt ligands. This phase Ib trial was designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RPh2) for IPA in combination with taxane and platinum therapy (C/P) Methods: Dose escalation started with a standard 3+3 design for IPA/C/P with q3w intravenous IPA on Day 1, in cycles 1 to 6 with C (AUC = 5 mg/mL · min) and P (175 mg/m2). For enhanced bone safety the trial was revised to 6-patient cohorts with a q3w regimen of IPA on Day 1 and C/P on Day 3 (IPA→C/P). Results: 37 patients have been treated; 30 of whom were treated following protocol revision to q3w IPA(D1)→C/P(D3) (2 & 4 mg/kg). IPA-related TEAEs that occurred in ≥15% included: fatigue (40%); nausea (35%); diarrhea and decreased appetite (22%) each; dysgeusia (19%); and vomiting (16.2%). 22% reported ≥1 IPA related TEAE Grade ≥3 the most common of which was neutropenia at 16%. There were no DLTs; the MTD was not reached. The maximum administered dose based on bone safety was 6mg/kg. The overall response rate (ORR) was 75.7%. Median PFS was 10.3 months (95% CI 8.5–14.2) and OS 33 months (95% CI 23.4- NR). Conclusions: IPA is well tolerated in combination with sequential C/P. ORR, PFS and OS are comparable to historical data but bone toxicity at efficacy doses of this particular Wnt inhibitor limit further development in EOC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2019.04.001

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 104

Metadata

Authors
Moore, K. N., Gunderson, C. C., Sabbatini, P., McMeekin, D. S., Mantia-Smaldone, G., Burger, R. A., Morgan, M. A., Kapoun, A. M., Brachmann, R. K., Stagg, R., Farooki, A., & O'Cearbhaill, R. E.
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2019-08
Volume
154
Issue
2
Pages
294-301
ISSN
0090-8258 (ISSN-L)
OpenAlex
W2948146865
Cited by
104
References
2
FWCI
11.15
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. https://app.cochat.ai/papers/10.1016/j.ygyno.2019.04.001
The paper
Moore, K. N., Gunderson, C. C., Sabbatini, P., McMeekin, D. S., Mantia-Smaldone, G., Burger, R. A., Morgan, M. A., Kapoun, A. M., Brachmann, R. K., Stagg, R., Farooki, A., & O'Cearbhaill, R. E. (2019). A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2019.04.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.